Latest Biogen Idec Inc (BIIB) Headlines Myriad
Post# of 122
Posted On: 03/13/2014 5:56:27 AM
Latest Biogen Idec Inc (BIIB) Headlines
Myriad Genetics Down on Court Ruling - Analyst Blog
Zacks Equity Research - Zacks Investment Research - Wed Mar 12, 2:30PM CDT
Shares of Myriad Genetics slashed 8.34% at yesterday's close, soon after an unfavorable court bid.
Can Biogen Catch up to Merck in Alzheimer's Race?
Cory Renauer, The Motley Fool - Motley Fool - Wed Mar 12, 1:30PM CDT
Drug development is a risky enterprise on its own. Advancing a safe and effective therapy for Alzheimer's disease (AD) is like trying to shoot the moon with a slingshot, blindfolded. The exact mechanism behind the formation of memories isn't entirely...
Biotech Stock Roundup: Amgen, Regeneron Slide on PCSK9 Inhibitor Concerns - Analyst Blog
Arpita Dutt - Zacks Investment Research - Wed Mar 12, 9:50AM CDT
Last week's highlights include safety concerns regarding a new class of drugs and takeover rumors.
Collaborations, Treatment Approvals, New Solutions, Clinical Trial Results, and New Drug Applications - Analyst Notes on Biogen Idec, Johnson & Johnson, Express Scripts, Merck, and Forest Laboratories
PR Newswire - Wed Mar 12, 7:00AM CDT
Today, Analysts Review released its analysts' notes regarding Biogen Idec Inc. (NASDAQ: BIIB), Johnson & Johnson (NYSE: JNJ), Express Scripts Inc. (NASDAQ: ESRX), Merck & Co. Inc. (NYSE: MRK), and Forest Laboratories Inc. (NYSE: FRX). Private wealth members receive these notes ahead of publication. To reserve complementary membership, limited openings are available at: http://www.AnalystsReview.com/register
Alexion Lifts 2014 View, Shares Up - Analyst Blog
Zacks Equity Research - Zacks Investment Research - Tue Mar 11, 12:42PM CDT
Alexion lifts outlook following French reimbursement deal on Soliris.
Stock Market News for March 11, 2014 - Market News
Zacks Equity Research - Zacks Investment Research - Tue Mar 11, 9:06AM CDT
Benchmarks finished Monday’s trading session nearly flat after recovering from day’s initial losses caused due to a drop in China’s export data and less-than-expected growth in Japan’s economy
Loss Widens at Peregrine, Shares Down - Analyst Blog
Zacks Equity Research - Zacks Investment Research - Tue Mar 11, 8:40AM CDT
Peregrine Pharma reported a net loss of 6 cents per share in the third quarter of fiscal 2014.
The Zacks Analyst Blog Highlights:Comscore, Apple, Google, Blackberry and Biogen Idec
PR Newswire - Tue Mar 11, 8:30AM CDT
Zacks.com announces the list of stocks featured in the Analyst Blog. Every day the Zacks Equity Research analysts discuss the latest news and events impacting stocks and the financial markets. Stocks recently featured in the blog include the Comscore (Nasdaq:SCOR-Free Report), Apple (Nasdaq:AAPL-Free Report), Google (Nasdaq:GOOG-Free Report), Blackberry (Nasdaq:BBRY-Free Report) and Biogen Idec Inc. (Nasdaq:BIIB-Free Report).
Wider Q4 Loss at Dynavax - Analyst Blog
Zacks Equity Research - Zacks Investment Research - Tue Mar 11, 8:10AM CDT
Dynavax Technologies reported a loss of 9 cents per share in the fourth quarter of 2013, wider than the Zacks Consensus Estimate of a loss of 7 cents.
InterMune Rises on Takeover Rumor - Analyst Blog
Zacks Equity Research - Zacks Investment Research - Mon Mar 10, 4:00PM CDT
Shares of InterMune were up around 10.8% on Mar 7 to end the day's trading at $33.87
Stocks Off Lows In Afternoon; Facebook Hits New High
at Investor's Business Daily - Mon Mar 10, 12:38PM CDT
Stocks came off their lows in afternoon trading Monday after a sell-off sparked by an unexpected drop in Chinese exports. The Dow Jones industrial average fell 0.3%, the S&P 500 was down 0.2% while the Nasdaq slipped 0.1%. Volume was weak, down 4% on...
Biogen Idec Shares Up 36.6% Since SmarTrend's Buy Recommendation (BIIB)
Comtex SmarTrend(R) - Mon Mar 10, 11:08AM CDT
SmarTrend identified an Uptrend for Biogen Idec (NASDAQ:BIIB) on November 19th, 2013 at $244.72. In approximately 4 months, Biogen Idec has returned 36.61% as of today's recent price of $334.31.
Biogen Upgraded to Strong Buy - Analyst Blog
Zacks Equity Research - Zacks Investment Research - Mon Mar 10, 10:40AM CDT
Biogen upgraded to Zacks Rank #1 (Strong Buy)
Global Hemophilia Market Report 2014-2018 with Baxter, Bayer, Novo Nordisk & Pfizer Dominating
M2 - Mon Mar 10, 9:49AM CDT
Research and Markets (http://www.researchandmarkets.com/research/7q98d5/global_hemophilia) has announced the addition of the "Global Hemophilia Market Report 2014-2018 with Baxter, Bayer, Novo Nordisk & Pfizer Dominating" report to their offering. Currently, most of the therapeutic hemophilia products are short acting, i.e., used only for when the patient suffers from bleeding. Further, many of these products exhibit immunogenic reactions resulting in a reduced effect of the therapeutic. In order to mitigate these issues, technologies such as PEGylation, recombinant DNA, and protein fusion technology, were developed and applied in the production of new therapies with a longer life span and fewer immunogenic reactions. For example, Biogen Idec is developing a next generation Hemophilia A therapy. The firm's leading therapeutic product, rFVIIIFc, is a recombinant - a truncated version of factor VIII, fused to the Fc domain of an antibody to extend half-life in the bloodstream. The resultant recombinant product is a result of Biogen's protein fusion technology. Thus, increase in technological innovations is expected to drive the Global Hemophilia market during the forecast period. According to the report, one of the major drivers in this market is the increase in the development of new hemophilia therapeutics. Currently, there are large number of products in the pipeline being developed by vendors which are aimed at addressing Hemophilia A, Hemophilia B, and von WilleBrand disease. The anticipated approval of these pipeline products is expected to contribute to the growth of the market during the forecast period. Further, the report states that one of the major challenges in this market is the high cost of hemophilia therapeutics. The high cost is attributed to the longer time taken to manufacture hemophilia prophylactics and manufacturing constraints. The key vendors dominating this market space are: - Baxter International Inc. - Bayer AG. - Novo Nordisk A/s-b. - Pfizer Inc. Key Topics Covered: 01. Executive Summary 02. List of Abbreviations 03. Scope of the Report 04. Market Research Methodology 05. Introduction 06. Market Landscape 07. Hemophilia Product Pipeline 08. Market Segmentation of Hemophilia Market by Type 09. Geographical Segmentation 10. Buying Criteria 11. Market Growth Drivers 12. Drivers and their Impact 13. Market Challenges 14. Impact of Drivers and Challenges 15. Market Trends 16. Trends and their Impact 17. Vendor Landscape 18. Key Vendor Analysis For more information visit http://www.researchandmarkets.com/research/7q...hemophilia
Aegerion Pharmaceuticals (AEGR) Soars: Stock Rises 10.6% - Tale of the Tape
Zacks Equity Research - Zacks Investment Research - Mon Mar 10, 8:39AM CDT
Aegerion Pharmaceuticals, Inc. was a big mover last session, as its shares rose nearly 11% on the day.
Zacks Rank #1 Additions for Monday - Tale of the Tape
Zacks Equity Research - Zacks Investment Research - Mon Mar 10, 8:30AM CDT
Here are 5 stocks added to the Zacks Rank #1 (Strong Buy) List for Monday
Emergent Beats on Earnings & Revenues, Shares Up - Analyst Blog
Zacks Equity Research - Zacks Investment Research - Mon Mar 10, 8:10AM CDT
Emergent had a strong quarter with both revenues and earnings coming above expectations.
Emergent BioSolutions (EBS) Soars: Stock Rises 8.6% - Tale of the Tape
Zacks Equity Research - Zacks Investment Research - Mon Mar 10, 7:51AM CDT
Emergent BioSolutions, Inc. was a big mover last session, as its shares rose nearly 9% on the day.
Better Buy: Biogen Or Amgen?
Todd Campbell, The Motley Fool - Motley Fool - Fri Mar 07, 5:30PM CST
Both Biogen and Amgen are succeeding thanks to fast growing therapies. At Biogen, Tecfidera continues its blistering pace forward in winning U.S. multiple sclerosis market share from Novartis and...
Biogen Idec Set to Possibly Rebound After Yesterday's Selloff of 3.50%
Comtex SmarTrend(R) - Fri Mar 07, 3:43PM CST
Biogen Idec (NASDAQ:BIIB) traded in a range yesterday that spanned from a low of $323.72 to a high of $342.85. Yesterday, the shares fell 3.5%, which took the trading range below the 3-day low of $334.01 on volume of 2.8 million shares. Often times after large one-day declines, short-term traders may play for some degree of mean reversion.
Myriad Genetics Down on Court Ruling - Analyst Blog
Zacks Equity Research - Zacks Investment Research - Wed Mar 12, 2:30PM CDT
Shares of Myriad Genetics slashed 8.34% at yesterday's close, soon after an unfavorable court bid.
Can Biogen Catch up to Merck in Alzheimer's Race?
Cory Renauer, The Motley Fool - Motley Fool - Wed Mar 12, 1:30PM CDT
Drug development is a risky enterprise on its own. Advancing a safe and effective therapy for Alzheimer's disease (AD) is like trying to shoot the moon with a slingshot, blindfolded. The exact mechanism behind the formation of memories isn't entirely...
Biotech Stock Roundup: Amgen, Regeneron Slide on PCSK9 Inhibitor Concerns - Analyst Blog
Arpita Dutt - Zacks Investment Research - Wed Mar 12, 9:50AM CDT
Last week's highlights include safety concerns regarding a new class of drugs and takeover rumors.
Collaborations, Treatment Approvals, New Solutions, Clinical Trial Results, and New Drug Applications - Analyst Notes on Biogen Idec, Johnson & Johnson, Express Scripts, Merck, and Forest Laboratories
PR Newswire - Wed Mar 12, 7:00AM CDT
Today, Analysts Review released its analysts' notes regarding Biogen Idec Inc. (NASDAQ: BIIB), Johnson & Johnson (NYSE: JNJ), Express Scripts Inc. (NASDAQ: ESRX), Merck & Co. Inc. (NYSE: MRK), and Forest Laboratories Inc. (NYSE: FRX). Private wealth members receive these notes ahead of publication. To reserve complementary membership, limited openings are available at: http://www.AnalystsReview.com/register
Alexion Lifts 2014 View, Shares Up - Analyst Blog
Zacks Equity Research - Zacks Investment Research - Tue Mar 11, 12:42PM CDT
Alexion lifts outlook following French reimbursement deal on Soliris.
Stock Market News for March 11, 2014 - Market News
Zacks Equity Research - Zacks Investment Research - Tue Mar 11, 9:06AM CDT
Benchmarks finished Monday’s trading session nearly flat after recovering from day’s initial losses caused due to a drop in China’s export data and less-than-expected growth in Japan’s economy
Loss Widens at Peregrine, Shares Down - Analyst Blog
Zacks Equity Research - Zacks Investment Research - Tue Mar 11, 8:40AM CDT
Peregrine Pharma reported a net loss of 6 cents per share in the third quarter of fiscal 2014.
The Zacks Analyst Blog Highlights:Comscore, Apple, Google, Blackberry and Biogen Idec
PR Newswire - Tue Mar 11, 8:30AM CDT
Zacks.com announces the list of stocks featured in the Analyst Blog. Every day the Zacks Equity Research analysts discuss the latest news and events impacting stocks and the financial markets. Stocks recently featured in the blog include the Comscore (Nasdaq:SCOR-Free Report), Apple (Nasdaq:AAPL-Free Report), Google (Nasdaq:GOOG-Free Report), Blackberry (Nasdaq:BBRY-Free Report) and Biogen Idec Inc. (Nasdaq:BIIB-Free Report).
Wider Q4 Loss at Dynavax - Analyst Blog
Zacks Equity Research - Zacks Investment Research - Tue Mar 11, 8:10AM CDT
Dynavax Technologies reported a loss of 9 cents per share in the fourth quarter of 2013, wider than the Zacks Consensus Estimate of a loss of 7 cents.
InterMune Rises on Takeover Rumor - Analyst Blog
Zacks Equity Research - Zacks Investment Research - Mon Mar 10, 4:00PM CDT
Shares of InterMune were up around 10.8% on Mar 7 to end the day's trading at $33.87
Stocks Off Lows In Afternoon; Facebook Hits New High
at Investor's Business Daily - Mon Mar 10, 12:38PM CDT
Stocks came off their lows in afternoon trading Monday after a sell-off sparked by an unexpected drop in Chinese exports. The Dow Jones industrial average fell 0.3%, the S&P 500 was down 0.2% while the Nasdaq slipped 0.1%. Volume was weak, down 4% on...
Biogen Idec Shares Up 36.6% Since SmarTrend's Buy Recommendation (BIIB)
Comtex SmarTrend(R) - Mon Mar 10, 11:08AM CDT
SmarTrend identified an Uptrend for Biogen Idec (NASDAQ:BIIB) on November 19th, 2013 at $244.72. In approximately 4 months, Biogen Idec has returned 36.61% as of today's recent price of $334.31.
Biogen Upgraded to Strong Buy - Analyst Blog
Zacks Equity Research - Zacks Investment Research - Mon Mar 10, 10:40AM CDT
Biogen upgraded to Zacks Rank #1 (Strong Buy)
Global Hemophilia Market Report 2014-2018 with Baxter, Bayer, Novo Nordisk & Pfizer Dominating
M2 - Mon Mar 10, 9:49AM CDT
Research and Markets (http://www.researchandmarkets.com/research/7q98d5/global_hemophilia) has announced the addition of the "Global Hemophilia Market Report 2014-2018 with Baxter, Bayer, Novo Nordisk & Pfizer Dominating" report to their offering. Currently, most of the therapeutic hemophilia products are short acting, i.e., used only for when the patient suffers from bleeding. Further, many of these products exhibit immunogenic reactions resulting in a reduced effect of the therapeutic. In order to mitigate these issues, technologies such as PEGylation, recombinant DNA, and protein fusion technology, were developed and applied in the production of new therapies with a longer life span and fewer immunogenic reactions. For example, Biogen Idec is developing a next generation Hemophilia A therapy. The firm's leading therapeutic product, rFVIIIFc, is a recombinant - a truncated version of factor VIII, fused to the Fc domain of an antibody to extend half-life in the bloodstream. The resultant recombinant product is a result of Biogen's protein fusion technology. Thus, increase in technological innovations is expected to drive the Global Hemophilia market during the forecast period. According to the report, one of the major drivers in this market is the increase in the development of new hemophilia therapeutics. Currently, there are large number of products in the pipeline being developed by vendors which are aimed at addressing Hemophilia A, Hemophilia B, and von WilleBrand disease. The anticipated approval of these pipeline products is expected to contribute to the growth of the market during the forecast period. Further, the report states that one of the major challenges in this market is the high cost of hemophilia therapeutics. The high cost is attributed to the longer time taken to manufacture hemophilia prophylactics and manufacturing constraints. The key vendors dominating this market space are: - Baxter International Inc. - Bayer AG. - Novo Nordisk A/s-b. - Pfizer Inc. Key Topics Covered: 01. Executive Summary 02. List of Abbreviations 03. Scope of the Report 04. Market Research Methodology 05. Introduction 06. Market Landscape 07. Hemophilia Product Pipeline 08. Market Segmentation of Hemophilia Market by Type 09. Geographical Segmentation 10. Buying Criteria 11. Market Growth Drivers 12. Drivers and their Impact 13. Market Challenges 14. Impact of Drivers and Challenges 15. Market Trends 16. Trends and their Impact 17. Vendor Landscape 18. Key Vendor Analysis For more information visit http://www.researchandmarkets.com/research/7q...hemophilia
Aegerion Pharmaceuticals (AEGR) Soars: Stock Rises 10.6% - Tale of the Tape
Zacks Equity Research - Zacks Investment Research - Mon Mar 10, 8:39AM CDT
Aegerion Pharmaceuticals, Inc. was a big mover last session, as its shares rose nearly 11% on the day.
Zacks Rank #1 Additions for Monday - Tale of the Tape
Zacks Equity Research - Zacks Investment Research - Mon Mar 10, 8:30AM CDT
Here are 5 stocks added to the Zacks Rank #1 (Strong Buy) List for Monday
Emergent Beats on Earnings & Revenues, Shares Up - Analyst Blog
Zacks Equity Research - Zacks Investment Research - Mon Mar 10, 8:10AM CDT
Emergent had a strong quarter with both revenues and earnings coming above expectations.
Emergent BioSolutions (EBS) Soars: Stock Rises 8.6% - Tale of the Tape
Zacks Equity Research - Zacks Investment Research - Mon Mar 10, 7:51AM CDT
Emergent BioSolutions, Inc. was a big mover last session, as its shares rose nearly 9% on the day.
Better Buy: Biogen Or Amgen?
Todd Campbell, The Motley Fool - Motley Fool - Fri Mar 07, 5:30PM CST
Both Biogen and Amgen are succeeding thanks to fast growing therapies. At Biogen, Tecfidera continues its blistering pace forward in winning U.S. multiple sclerosis market share from Novartis and...
Biogen Idec Set to Possibly Rebound After Yesterday's Selloff of 3.50%
Comtex SmarTrend(R) - Fri Mar 07, 3:43PM CST
Biogen Idec (NASDAQ:BIIB) traded in a range yesterday that spanned from a low of $323.72 to a high of $342.85. Yesterday, the shares fell 3.5%, which took the trading range below the 3-day low of $334.01 on volume of 2.8 million shares. Often times after large one-day declines, short-term traders may play for some degree of mean reversion.
(0)
(0)Biogen Inc. (BIIB) Stock Research Links
Scroll down for more posts ▼